WhyNotDry will deepen our knowledge on reversible drying in cells and germplasm toward the development of a dry biobanking as an alternative to the current freezing in Liquid Nitrogen (LN). LN is expensive, requires dedicated facilities and power supply, and has a high CO2 footprint. WhyNotDry will achieve its aims through a multidisciplinary, intersectoral, international network of scientists that will: i) Develop a drying/rehydration platform using naturally desiccation-tolerant midge (Polypedilum vanderplanki) Pv11 cell lines; ii) Identify the best combination of naturally occurring xeroprotectants (xero=dry) from desiccation-tolerant insect cell line and the best performing water subtraction platform. iii) To use the best xeroprotectants mix and the drying/rehydration protocol for mammalian cells/germplasm. vi) Develop a prototype for controlled dehydration of microvolumes of cell. The R&I activities leading to these aims will be carried out by knowhow sharing through Staff Exchanges between: 3 EU academies, 2 EU SMEs, 2 international partners (Japan, Thailand). Outcomes of WhyNotDry will be incorporated into a cheap, environmentally friendly, and easy biobanking for biodiversity conservation, assisted reproduction, stem cell/personalized medicine. Successful development of this technology will set the basis for a radically new, ‘green’ biobanking paradigm, simplifying the maintenance and shipping practices in life sciences, with enormous reduction in costs and carbon footprint. Moreover, knowledge generated in WhyNotDry would be applicable to other fields such as agriculture, environmental science, food processing, and the pharmaceutical industry, where elective or enforced (by climate change) drying is dealt with. Finally, WhyNotDry will empower young scientists with transferable skills, ensuring career prospects in academia/industry, and strengthen the international/sectorial network between disciplines, boosting European excellence.

Cardiovascular diseases (CVDs) account for 45% of deaths in Europe and are estimated to cost the EU economy €210 billion a year. However, only four drugs targeting cardiovascular diseases have been approved for use in the last decade. Thus, models that could effectively simulate diseased tissues, would enable the accurate assessment of the efficacy of the pharmaceuticals, and would accelerate drug development are urgently needed. The main bottleneck towards such models is the foetal-like state of the human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (CMs). That is hiPSC-CMs do not reach adult-like maturity. The objective of this project is to produce a platform for growth and maturation of cardiac microtissues for adult-like organotypic models in healthy and diseased states. To achieve that, biomimetic microenvironment that provides all the needed stimuli (electrical, mechanical, topological (3D environment) and biochemical (release of active molecules)), during the maturation of hiPSC-CMs will be developed. This will be achieved by combining electro-mechanoactive polymer-based scaffolds (EMAPS) with bioactive membranes. To characterize the effects of CVD drugs, the contractility of the microtissue will be monitored continuously and simultaneously (over 24-wells) using the sensors developed during the project. To increase the sensitivity and accuracy of the model, deep-learning based algorithms to detect the effects of drugs in vitro will be developed and verified. The goals will be achieved by a multidisciplinary consortium with complementary know-how of three academic units and seven small companies. The increased sensitivity and accuracy of organ-on-chip devices is a needed leap in technology that will accelerate new drug development without the need for animal models; the project aims to provide a platform for the realization of such physiologically-relevant organotypic models.